Subsequent research revealed that the loss of LSD1 led to enhanced T‐cell infiltration and immunogenicity in response to anti‐PD1 therapy in a melanoma mouse model, suggesting the potential for combination therapy utilizing LSD1 inhibitors and anti‐PD‐(L)1.82 This evidence concerns the gene KDM1A and melanoma.